KCAS Bio will participate in AAPS 2025 PharmSci 360, taking place November 9-12 in San Antonio, TX. Stop by Booth #3034 to meet our team in person.
Don’t miss Dawn Dufield, Ph.D.’s session where she’ll discuss “Bioanalytical Strategies for Therapeutic Drugs and Their Conjugates (ADCs, Oligos, siRNA, ASOs and AOCs/ARCs) by QqQ/HRMS. Strategies and Case Studies”.
Tuesday, November 11th at 3:30 PM
The landscape of bioanalysis is evolving alongside novel therapeutic modalities. Hybrid LC-MS/MS has become a cornerstone for both quantitative and structural characterization of complex conjugated therapeutics, including ADCs, ARCs, and oligonucleotide-based drugs.
In this talk, Dawn will highlight:
- How hybrid LC-MS/MS workflows monitor total antibodies, conjugated payloads like siRNA or ASO, and toxic components
- Key bioanalytical challenges in characterizing conjugated therapeutics
- Case studies demonstrating robust strategies for supporting drug development across oncology, genetic, and rare disease indications
Attendees will gain practical insights into how advanced LC-MS/MS workflows enable comprehensive characterization, streamline development, and help bring these next-generation therapies from the lab to patients. Mark your calendars!
Pharmaceutical Sciences at KCAS Bio
AAPS 2025 PharmSci 360 gathers industry professionals for a conference that covers the full spectrum of drug development. Topics will cover preclinical research, bioanalytics, clinical pharmacology, formulation, manufacturing, and regulatory science. These topics converge innovation, policy, and professional development, providing a 360-degree view of the pharmaceutical sciences. The comprehensive program will feature presentations, interactive exhibits, and networking- all designed to spark collaboration and advance innovation across the pharmaceutical industry.
KCAS Bio provides advanced bioanalytical and biomarker development services that align closely with the scope of AAPS PharmSci 360. Our expertise spans regulated and non-regulated assay development to support pharmacokinetic, pharmacodynamic, and immunogenicity assessments across a broad range of therapeutic platforms. We leverage advanced technologies to generate decision-enabling data that accelerate the stages of drug development. Our scientific teams work collaboratively with sponsors to design fit-for-purpose assays that meet evolving regulatory expectations and complex study requirements.
Connect With Us at AAPS 2025 PharmSci 360
Meet with our team at AAPS 2025 PharmSci 360 to discuss drug development across every stage. Our team, including Dominic Warrino, Dawn Dufield, Jonathan Mercier, Adriane Csikos, and Breanna Fowler will be at Booth #3034 to share our expertise and ignite collaboration that advances your bioanalytical projects.